
    
      Eligible seniors will be randomly placed into three groups to receive 400 mg/day, 800mg/day
      or a placebo for a period of six months beginning in October. Daily dosing will be recorded
      as well as any symptoms not related to having a respiratory infection. For seniors who
      experience a respiratory infection, they are asked to call a study nurse who will take a
      nasopharyngeal swab. The seniors are also asked to record on a diary card the severity of
      their symptoms on a scale from 0-3 (none, mild, moderate, severe). Symptoms include cough,
      fever, runny nose, stuff nose, aches and pains, headache, chills, sneezing, ear aches and
      fatigue.The swab will be taken to the lab for testing for upper respiratory viruses.
    
  